Deep sequencing reveals subpopulation dynamics associated with treatment failure in a rare non-tuberculous mycobacterial infection

Background Nontuberculous mycobacteria (NTM) are an increasingly common group of pathogens that remain challenging to diagnose and treat effectively. The lack of standardization of NTM management, from identification to antibiotic resistance prediction, results in imperfect correlations between treatment and outcomes. This study characterizes the genetic heterogeneity of a previously uncharacterized NTM during a 29-month bacteremia with acquired drug resistance. Results In contrast to the initial diagnostic result identifying M. nebraskense, a rare NTM causing disease in humans, whole genome sequencing (WGS) identified Mycobacterium sp. SMC-2, a species with only one publicly available genome. High-resolution analysis of variants revealed 444 unique SNPs and 26 indels in 12 longitudinal isolates, with the highest number of low-frequency mutations between 3-5% frequency. Seven candidate drug-resistance mutations across five evolutionary trajectories showed frequency shifts that correlated with changes in minimum inhibitory concentrations to the corresponding antibiotics. These included a 23S rRNA clarithromycin-resistance SNP detected at 7% frequency when phenotypic resistance emerged, suggesting that low-frequency variants drive subpopulation evolution. Acquisition of drug resistance during therapy was associated with several low-frequency mutations in genes associated with resistance to antibiotics, including clarithromycin and quinolones, in other NTM species. Conclusion This study highlights the importance of low-frequency variants as drivers of intra-patient bacterial population diversity, allowing subpopulations to adapt to antibiotic pressure and ultimately contributing to treatment failure. Additionally, it underscores their potential implications for the development of molecular diagnostic tests for NTM resistance prediction.